Boehringer Ingelheim International GmbH — Sponsor Intelligence | 163 EU Trials

Filter these 163 trials by condition, phase, country and more.

Open in Search →

163 Registered trials

37 Recruiting

130 Completed trials

25 Countries active

56 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I

Phase I (Other)

Phase III: 23 Phase II/III: 4 Phase II: 23 Phase I/II: 3 Phase III/IV: 1 Phase I: 21 Phase I (Other): 82 Phase I (FiH): 1 Other: 5

Oversight events:

4 serious breaches 86 temporary halts 3 corrective measures across 23 trials

View oversight register →

100%

130 of 130 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Obesity 4 Neuroendocrine carcinoma 2 Bronchiectasis 2 Non-small cell lung cancer 2 Portal hypertension 2 Small cell lung cancer extensive stage 2 Cystic fibrosis lung 2 Pancreatic carcinoma 1 Small cell lung cancer 1 Acute myocardial infarction 1 Cystic fibrosis 1 Glioma 1

Top IMPs

SPESOLIMAB 6 ZONGERTINIB 5 (3S,3'S,3A'S,10A'S)-6-CHLORO-3'-(3-CHLORO-2-FLUOROPHENYL)-1'-(CYCLOPROPYLMETHYL)-6'-METHYL-2-OXO-1,2,3',3A',10',10A'-HEXAHYDRO-1'H-SPIRO[INDOLE-3,2'-PYRROLO[2',3':4,5]PYRROLO[1,2-B]INDAZOLE]-7'-CARBOXYLIC ACID 4 [4-(6-AMINOPYRIDAZIN-3-YL)PIPERIDIN-1-YL][5-(4-FLUOROPHENOXY)-4-METHOXYPYRIDIN-2-YL]METHANONE 4 1-[[(5R)-2-[4-(5-CHLORO-2-PYRIMIDINYL)-1-PIPERIDINYL]-6,7- DIHYDRO-5-OXIDOTHIENO[3,2-D]PYRIMIDIN-4- YL]AMINO]-CYCLOBUTANEMETHANOL 4 BI 1015550 4 BI 1291583 4 BI 456906 4 BI 690517 4 CARBOPLATIN 4 SURVODUTIDE 4 BI 685509 3

All trials — page 7

163 total

A study in healthy men to test how BI 764198 is processed in the body Ended

2022-502327-22-00 Phase I (Other) 1 country [4-(6-AMINOPYRIDAZIN-3-YL)PIPERIDIN-1-YL][5-(4-FLUOROPHENOXY)-4-METHOXYPYRIDIN-2…
A study in healthy men to test how BI 1291583 is processed in the body Ended

2022-502264-20-00 Phase I (Other) 1 country BI 1291583
A study to compare how different substances (caffeine, warfarin, omeprazole, metoprolol, and midazolam) are handled by the body of healthy p… Ended

2024-514622-22-00 Phase I (Other) 1 country
Safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous and subcutaneous multiple rising doses of BI 765250 versus place… Ended

2024-512420-10-00 Phase I (Other) 2 countries
A study to test whether BI 907828 helps people with cancer in the biliary tract, pancreas, lung, or bladder Ended

2023-506369-79-00 Phase II 5 countries (3S,3'S,3A'S,10A'S)-6-CHLORO-3'-(3-CHLORO-2-FLUOROPHENYL)-1'-(CYCLOPROPYLMETHYL)…
A study in people with systemic sclerosis to test whether BI 685509 has an effect on lung function and other systemic sclerosis symptoms Ended

2022-500332-11-00 Phase II 17 countries BI 685509
A study in healthy women to test whether BI 425809 influences the amount of a contraceptive in the blood Ended

2022-500050-42-00 Phase I (Other) 1 country ETHINYLESTRADIOL, LEVONORGESTREL; ICLEPERTIN
A study to find out whether BI 1015550 improves lung function in people with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) Ended

2024-512803-37-00 Phase III 19 countries 1-[[(5R)-2-[4-(5-CHLORO-2-PYRIMIDINYL)-1-PIPERIDINYL]-6,7- DIHYDRO-5-OXIDOTHIENO…
A study to test whether BI 685509 alone or in combination with empagliflozin helps people with liver cirrhosis caused by viral hepatitis or … Ended

2023-504257-12-00 Phase II 9 countries BI 685509
A study in people with advanced cancer to test whether the amount of BI 907828 in the blood is influenced by taking an OATP inhibitor or a C… Ended

2024-514532-24-00 Phase I (Other) 2 countries
A study in patients with different types of advanced cancer (solid tumors) to test different doses of BI 907828 (brigimadlin) in combination… Ended

2024-511352-41-00 Phase I (Other) 6 countries
A study to test BI 764198 in people with a type of kidney disease called focal segmental glomerulosclerosis Ended

2024-511706-23-00 Phase II 5 countries [4-(6-AMINOPYRIDAZIN-3-YL)PIPERIDIN-1-YL][5-(4-FLUOROPHENOXY)-4-METHOXYPYRIDIN-2…
A study to evaluate long-term safety of nintedanib in children and adolescents with interstitial lung disease (InPedILD®-ON) Ended

2024-515743-27-00 Phase III 8 countries NINTEDANIB
A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study Ended

2024-511560-93-00 Phase III 21 countries ICLEPERTIN
Brightline-1: A study to compare brigimadlin (BI 907828) with doxorubicin in people with a type of cancer called dedifferentiated liposarcom… Ended

2024-511361-11-00 Phase II/III 12 countries (3S,3'S,3A'S,10A'S)-6-CHLORO-3'-(3-CHLORO-2-FLUOROPHENYL)-1'-(CYCLOPROPYLMETHYL)…
A study to test whether BI 706321 combined with ustekinumab helps people with Crohn's Disease Ended

2024-512756-38-00 Phase II 6 countries BI 706321; USTEKINUMAB
This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors) Ended

2024-511503-41-00 Phase I (Other) 6 countries
A study to test different doses of BI 1823911 alone and combined with other medicines in people with different types of advanced cancer with… Ended

2024-512805-18-00 Phase I (Other) 2 countries
Brightline-4: A study to test how well brigimadlin is tolerated by people with a type of cancer called dedifferentiated liposarcoma Ended

2023-504522-19-00 Phase III 2 countries (3S,3'S,3A'S,10A'S)-6-CHLORO-3'-(3-CHLORO-2-FLUOROPHENYL)-1'-(CYCLOPROPYLMETHYL)…

Showing 145–163 of 163 trials

← All sponsors A–Z